🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "huge turning point" in the effort against superbug strains of the bacteria, according to scientists.

A Global Health Concern

Gonorrhoea infections are escalating around the world, with figures suggesting more than 82 million infections per year. Especially elevated rates are seen in the African continent and countries within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary step in the reality of rising global incidence, escalating drug resistance and the very limited treatment choices currently available.”

Medical experts are increasingly worried about the surge in drug-resistant strains. The global health body has designated it as a "critical concern". Recent surveillance showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Receive Approval

Zoliflodacin, also known as Nuzolvence, was authorized by the American regulatory agency in recent days for combating gonorrhoea. This STI can lead to significant complications, including infertility. Experts anticipate that focused deployment of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This medication, which is employed against UTIs, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a new, not-for-profit approach for medication research. The charitable organization GARDP partnered with the drug firm Innoviva to bring it to fruition.

“This milestone represents a huge turning point in the therapy of superbug gonorrhoea, which up to this point has been outpacing medical innovation.”

Clinical Trial Results and Worldwide Availability

Based on results published in a prominent scientific publication, zoliflodacin successfully treated more than 90% of cases of the STI. This establishes an equal footing with the typical regimen, which uses two antibiotics. The research enrolled nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the rights to register and commercialise the drug in many low-income and middle-income countries.

Clinicians directly involved have voiced positive views. Access to a easy-to-administer therapy of this kind is described as a "critical tool" for gonorrhoea control. This is considered essential to alleviate the strain of the illness for people and to stop the proliferation of highly drug-resistant gonorrhoea around the world.